GPX3 and breast cancer: Previously in the cohort used in this study, serum Se, serum SELENOP concentrations, activity of the serum GPx3 as well as novel autoantibodies targeting SELENOP were shown to be independent predictors of survival after breast cancer diagnosis, outperforming established clinical prognostic markers [4, 5].